Jul. 30 at 11:12 PM
$ABCL
When I wrote this, the Jazz partnership was my latest evidence.
Now Vertex has followed.
Two major pharmaceutical companies have committed
$84M in combined upfront payments to access AbCellera’s T-cell engager platform while funding the partnered R&D and leaving
$ABCL
with milestone and royalty upside.
One partnership can be dismissed as a deal.
Two major partners arriving back-to-back begins to look like repeatable platform validation.
The
$20B thesis will not be proven by one partnership or one drug. It depends on AbCellera repeatedly creating valuable medicines for partners and for itself.
Jazz was evidence.
Vertex is more evidence.
ABCL635 Phase 2 is the next major test.
I’ll keep documenting the thesis, the numbers and the risks as the evidence develops.
Follow if you’re interested in where this story goes.
